Drug ID:Drug172
Drug Name:BMS-986251
CID:132123624
DrugBank ID:DB19007
Modality:Small Molecule
Groups:NULL
US Approved:NULL
Other Approved:NULL
Identifier: NCT03329885
Molecular Formula:C30H29F8NO5S
Molecular Weight:667.6 g/mol
Isomeric SMILES:C[C@H]1C[C@@H](CC[C@H]1C(=O)N2CC[C@@]3([C@H]2CCC4=C3C=CC(=C4)C(C(F)(F)F)(C(F)(F)F)F)S(=O)(=O)C5=CC=C(C=C5)F)C(=O)O
Synonyms:BMS-986251; UNII-2WQX2MS3MQ; 2WQX2MS3MQ; (1R,3S,4R)-4-((3aR,9bR)-9b-((4-Fluorophenyl)sulfonyl)-7-(perfluoropropan-2-yl)-2,3,3a,4,5,9b-hexahydro-1H-benzo(E)indole-3-carbonyl)-3-methylcyclohexane-1-carboxylic acid; 2041841-30-7; 2460133-35-9; (1R,3S,4R)-4-[(3aR,9bR)-9b-[(4-fluorophenyl)sulfonyl]-7-(1,1,1,2,3,3,3-heptafluoropropan-2-yl)-1,2,3a,4,5,9b-hexahydro-3H-benzo[e]indole-3-carbonyl]-3-methylcyclohexane-1-carboxylic acid; CHEMBL4634542; SCHEMBL19592747; JQORWGARJVSRBA-QOTTZFGFSA-N
Phase 0: 0
Phase 1: 0
Phase 2: 0
Phase 3: 0
Phase 4: 0
Description:NULL

Molecular Structure

2D Molecular Structure

Knowledge Graph

dtIDCIDCompound NameGene IDGene NameSpeciesPubMed IDsAction
No data available

  • No data available

Phase Distribution
Phase Description
  • Phase 0: Exploratory trials to assess drug behavior in humans
  • Phase 1: Safety trials to determine safe dosage range
  • Phase 2: Efficacy trials to evaluate therapeutic effects
  • Phase 3: Large-scale trials to confirm efficacy and safety
  • Phase 4: Post-marketing surveillance for long-term safety and efficacy

Trial IDTitlePhaseStatusSponsorIndicationsInterventions
NCT03329885 A Study of Experimental Medication BMS-986251, Taken by Mouth, in Healthy Participants and Patients With Average to Very Serious Psoriasis PHASE1|PHASE2 TERMINATED Bristol-Myers Squibb Rheumatoid Arthritis|Psoriasis|Ankylosing Spondyl… DRUG: BMS-986251|OTHER: Placebo Details
NCT05687474 Baby Detect : Genomic Newborn Screening NULL COMPLETED Centre Hospitalier Universitaire de Liege Congenital Adrenal Hyperplasia|Familial Hyperinsu… None Details
NCT05666960 R-3750 in Patients With Mild to Moderate Ulcerative Colitis PHASE1 RECRUITING Rise Therapeutics LLC Ulcerative Colitis Chronic Mild|Ulcerative Coliti… DRUG: R-3750 Details
NCT05659953 LMT503 First-in-human SAD, MAD, and FE Study PHASE1 NOT_YET_RECRUITING Lmito Therapeutics Inc. Inflammatory Bowel Disease|Colitis, Ulcerative|Cr… DRUG: LMT503|DRUG: Placebo Details
NCT05624801 Cholecalciferol Comedication in Patients With Chronic Inflammatory Bowel Diseases (Crohn's Disease or Ulcerative Colitis) - the 5C-study PHASE3 Recruiting University Hospital, Basel, Switzerland IBD Drug: D3 VitaCaps Details
NCT05588843 Dose-finding Study of SAR443122 in Adult Participants With Ulcerative Colitis PHASE2 ACTIVE_NOT_RECRUITING Sanofi Colitis Ulcerative DRUG: SAR443122|DRUG: Placebo Details
NCT05528510 A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis PHASE3 ACTIVE_NOT_RECRUITING Janssen Research & Development, LLC Colitis, Ulcerative DRUG: Guselkumab Dose 1|DRUG: Guselkumab Dose 2|D… Details
NCT07161297 Remimazolam for Colonoscopy in IBD Patients PHASE4 NOT_YET_RECRUITING Humanitas Clinical and Research Center IBD (Inflammatory Bowel Disease) DRUG: Intravenous remimazolam (5 mg initially, wi… Details
NCT05509777 A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease PHASE3 RECRUITING Eli Lilly and Company Crohn's Disease DRUG: Mirikizumab Details
NCT05507931 Broccoli Sprouts for Mild Ulcerative Colitis NA COMPLETED University of Michigan Ulcerative Colitis|Ulcerative Colitis Chronic Mild DIETARY_SUPPLEMENT: 1 Serving of broccoli sprouts… Details
NCT05377580 A Study to Evaluate IBI112 in the Treatment of Moderate to Severe Active Ulcerative Colitis PHASE2 COMPLETED Innovent Biologics (Suzhou) Co. Ltd. Ulcerative Colitis (UC) DRUG: Period 1 IBI112 Placebo|DRUG: Period 2 IBI1… Details
NCT07149441 Efficacy and Mechanism of FMT in the Treatment of Inflammatory Bowel Disease: an Open-label Randomized Controlled Study NA ACTIVE_NOT_RECRUITING Shanghai 10th People's Hospital Inflammatory Bowel Disease (Crohn&Amp;#39;s Disea… PROCEDURE: Fecal microbiota transplantation|DRUG:… Details
NCT05271838 Protein and Magnesium in Ulcerative Colitis NA UNKNOWN University of Aarhus Inflammatory Bowel Diseases|Colitis, Ulcerative|M… DIETARY_SUPPLEMENT: Magnesium acetate mixture (30… Details
NCT07132333 Molecular Inflammation Board at the Center for Personalized Medicine NULL RECRUITING University Hospital Tuebingen Psoriasis (PsO)|Psoriasis Arthritis|Inflammatory … BIOLOGICAL: Biologic Agent Details
NCT05242484 A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis PHASE2 ACTIVE_NOT_RECRUITING Janssen Research & Development, LLC Colitis, Ulcerative BIOLOGICAL: Guselkumab|BIOLOGICAL: Golimumab|BIOL… Details
NCT05242471 A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease PHASE2 ACTIVE_NOT_RECRUITING Janssen Research & Development, LLC Crohn's Disease BIOLOGICAL: Guselkumab|BIOLOGICAL: Golimumab|BIOL… Details
NCT07123350 Evaluating the Shift From Intravenous to Subcutaneous Vedolizumab for Inflammatory Bowel Disease NULL ACTIVE_NOT_RECRUITING Vanderbilt University Medical Center Inflammatory Bowel Disease (IBD)|Crohn&Amp;#39;s … DRUG: Patient switched from IV vedolizumab to sub… Details
NCT07123259 Ulcer Pomegranate Muffins NA COMPLETED University of Lahore Gastric|Peptic Ulcer DIETARY_SUPPLEMENT: WHOLE WHEAT MUFFIN|COMBINATIO… Details
NCT05197049 A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease PHASE3 ACTIVE_NOT_RECRUITING Janssen Research & Development, LLC Crohn Disease DRUG: Guselkumab Dose 1|DRUG: Guselkumab Dose 2|D… Details
NCT05181137 A Phase 3 Study to Investigate the Efficacy and Safety of SHR0302 With Moderately to Severely Active Ulcerative Colitis PHASE3 UNKNOWN Reistone Biopharma Company Limited Ulcerative Colitis DRUG: SHR0302|DRUG: Placebo Details

Disease IDDisease NameDefinitionCategoryRelated DrugsMechanism
No data available

Strategy IDTherapeutic StrategySynonymsRelated DrugsMechanism
S01 Anti-inflammatory inflammatory 5-Aminosalicylates (5-ASAs); corticosteroids Crohn's disease and ulcerative colitis are the two main com… Details
S04 T-cell homing and retention T-cell trafficking vedolizumab; anti-MAdCAM1 antibodies ; etrolizumab Inhibition of the interaction between α4β7 integrins on T c… Details
S06 Anti-fibrosis fibrosis; tissue remodelling GS-5745; STNM01 Tissue remodelling and destruction in patients with IBD is … Details
S07 Blockade of cytokine Cytokine signalling apremilast; roflumilast; filgotinib; tofacitinib; ABT494; ABT-874; ustekinumab; isankizumab; LY-2525623; AMG139; MEDI2079; guselkumab Various T-cell subsets, their differentiation pathways and … Details

No related literature

You can run management commands to establish drug-literature associations